“This study shows that a single receptor may play various roles depending on whether its site of action is in the nucleus or on the cell membrane,” states Dr. Jean-Sï¿½bastien Joyal, MD, PhD, a pediatric intensivist at the Sainte-Justine UHC and an assistant professor at the Universitï¿½ de Montrï¿½al. The groundbreaking discovery has significant clinical implications, since many drugs act on this family of receptors irrespective of their site of action in the cell. “Our results are extremely encouraging. They indicate that drugs formulated to target this nuclear receptor may one day prevent retinopathy in premature babies,” continued Dr. Sylvain Chemtob, a neonatologist at Sainte-Justine and a full professor in Pediatrics, Ophthalmology and Pharmacology at the Universitï¿½ de Montrï¿½al.
Abnormal proliferation of blood vessels may lead to a number of disorders. Therefore, the finding may offer therapeutic potential for other conditions, particularly proliferative diabetic retinopathy and cancer. This potential still needs to be explored.
source : http://www.sciencedaily.com/releases/2014/09/140916092013.htm